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I. Introduction
The American College of Cardiology (ACC)/American Heart
Association (AHA) Task Force on Practice Guidelines regularly
reviews existing guidelines to determine when an update or full
revision is needed. Guidelines for the Clinical Use of Cardiac
Radionuclide Imaging were originally published in 1986 and
updated in 1995. Important new developments have continued to
occur since 1995, particularly in the areas of acute and chronic
ischemic syndromes and heart failure. The Task Force therefore
believed the topic should be revisited de novo and invited the
American Society for Nuclear Cardiology (ASNC) to cosponsor the
undertaking, which represents a joint effort of the 3 organizations.
The full-text guideline is available on the Internet (www.acc.org,
www.americanheart.org, and www.asnc.org). It discusses the use-
fulness of nuclear cardiological techniques in 3 broad areas: acute
ischemic syndromes, chronic syndromes, and heart failure. Utility is
considered for diagnosis, severity of disease/risk assessment/prog-
nosis, and assessment of therapy. An appendix provides descrip-
tions of individual techniques. This Executive Summary includes
recommended indications for the use of specific techniques and
summary evaluations of topics addressed in the full-text document.
Additional supporting evidence and a complete reference list are
presented in the full-text document.
The current guideline overlaps with several previously
published ACC/AHA guidelines for patient treatment that
potentially involve cardiac radionuclide imaging. These in-
clude published guidelines for chronic stable angina (SA;
2002), unstable angina and non–ST-elevation myocardial
infarction (UA/NSTEMI; 2002), heart failure (2001), periop-
erative cardiovascular evaluation for noncardiac surgery
(2002), exercise testing (2002), valvular heart disease (1998),
and acute myocardial infarction (AMI; 1999). The present
report is not intended to include information previously
covered in these guidelines or to provide a comprehensive
treatment of the topics addressed in these guidelines.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment
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IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy
IIb: Usefulness/efficacy is less well established by
evidence/opinion
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treat-
ment is not useful/effective and in some cases
may be harmful
Levels of evidence for individual class assignments are
designated as follows:
A: Data derived from multiple randomized clinical trials
B: Data derived from a single randomized trial or from
nonrandomized studies
C: Consensus opinion of experts
These guidelines will be reviewed annually by the Task
Force and will be considered current unless the Task Force
revises or withdraws them from distribution.
II. Acute Syndromes
A. Myocardial Perfusion Imaging in the
Assessment of Patients Presenting With Chest Pain
to the Emergency Department
Optimal decision-making in patients seen in the emergency
department with chest pain requires triage into risk categories
on the basis of the probability of AMI, UA, or both and the
subsequent risk and potential interventional options. Within
such an algorithm, radionuclide imaging provides clinically
useful information for diagnosis and management. The UA
guidelines use 4 risk levels for chest pain: noncardiac, chronic
SA, possible acute coronary syndrome (ACS), and definite
ACS (http://www.acc.org/clinical/guidelines/unstable/
unstable.pdf) (1). Radionuclide imaging is most appropriate
in patients with possible ACS. After initial triage on the basis
of symptoms, ECG, and history, rest single-photon emission
CT (SPECT) imaging appears to be useful for identifying
patients at high risk (those with perfusion defects), who
should be admitted, and patients with low risk (those with
normal scans), who in general may be discharged home with
a low risk for subsequent ischemic events. Randomized
clinical trials (2,3) now support several observational studies
(see Table 1 in the full-text guideline) indicating a high
negative predictive value for excluding ACS. Table 1 lists
recommendations for emergency department imaging for
suspected ACS.
B. Detection of AMI When Conventional Measures
Are Nondiagnostic
Rest myocardial perfusion imaging with 99mTc tracers has a
high sensitivity for diagnosing AMI. Because there is mini-
mal redistribution of the radiopharmaceutical over time,
imaging can be delayed for a few hours after the injection and
still provide accurate information about myocardial perfusion
at the time of injection, which reflects the area of myocardi-
um at risk. Perfusion defects, however, do not distinguish
among acute ischemia, acute infarction, or previous
infarction.
C. Radionuclide Testing in Risk Assessment:
Prognosis and Assessment of Therapy
After STEMI
As discussed in the ACC/AHA Guidelines for the Manage-
ment of Patients with Acute Myocardial Infarction: 1999
Update (4) (http://www.acc.org/clinical/guidelines/nov96/
1999/index.htm), the prognosis of STEMI is primarily a
function of ejection fraction (EF), infarct size, and residual
myocardium at risk. Thus, acute or late measurement of EF,
infarct size, and myocardium at risk provides important
prognostic management information. Radionuclide tech-
niques are also useful for assessing the presence and extent of
stress-induced myocardial ischemia—information that is use-
ful for immediate and long-term patient management (5–9).
Table 2 lists recommendations for radionuclide testing in
diagnosis, risk assessment, prognosis, and assessment of
therapy after acute STEMI.
D. Radionuclide Testing in Risk Assessment:
Prognosis and Assessment of Therapy After
NSTEMI or UA
The ACC/AHA 2002 Guideline Update for the Management
of Patients with UA/NSTEMI (1) recommends an early
invasive strategy in patients with any of several high-risk
TABLE 1. Recommendations for Emergency Department Imaging for Suspected ACS
Indication Test Class
Level of
Evidence
1. Assessment of myocardial risk in possible ACS patients with
nondiagnostic ECG and initial serum markers and enzymes, if available.
Rest MPI I A
2. Diagnosis of CAD in possible ACS patients with chest pain with
nondiagnostic ECG and negative serum markers and enzymes or normal
resting scan.
Same day rest/stress
perfusion imaging
I B
3. Routine imaging of patients with myocardial ischemia/necrosis already
documented clinically, by ECG and/or serum markers or enzymes
Rest MPI III C
See Figure 6 of ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment
Elevation Myocardial Infarction at http://www.acc.org/clinical/guidelines/unstable/incorporated/figure6.htm and Figure 1 of ACC/AHA
Guidelines for the Management of Patients with Acute Myocardial Infarction at www.acc.org/clinical/guidelines/nov96/1999/
jac1716f01.htm.
ACS indicates acute coronary syndromes; CAD, coronary artery disease; ECG, electrocardiogram; MPI, myocardial perfusion
imaging.
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indicators and no serious comorbidities. High-risk findings on
noninvasive stress testing (eg, myocardial perfusion imaging)
are one such indication. In the absence of high-risk findings,
the guidelines endorse either an early conservative or early
invasive strategy in patients without contraindications for
revascularization. Myocardial perfusion imaging is particu-
larly useful in the predischarge risk stratification of patients
with UA. The presence and extent of reversible perfusion
defects on stress testing after the patient is stabilized are
highly predictive of future events (10–14). Table 3 lists
recommendations for radionuclide testing for risk assess-
ment/prognosis in patients with NSTEMI or UA.
III. Chronic Syndromes
A. Detection (Diagnosis) of Coronary Artery Disease
A thorough discussion of the concepts of likelihood of
coronary artery disease (CAD) is provided in the ACC/AHA
2002 Guideline Update for the Management of Patients With
Chronic Stable Angina (15) (http://www.acc.org/clinical/
guidelines/stable/stable_clean.pdf), accompanied by a simpli-
fied table for estimating pretest probability ranges. Myocar-
dial perfusion imaging is most useful in patients with an
intermediate likelihood of angiographically significant CAD
on the basis of age, sex, symptoms, risk factors, and the
results of stress testing (for patients who have undergone
prior stress testing).
1. Sensitivity and Specificity
Tables 5 and 6 in the full-text guideline summarize studies
reporting sensitivities and specificities of exercise and vaso-
dilator stress perfusion SPECT for the detection of angio-
graphically significant (more than 50% stenosis) CAD. Sen-
sitivities (generally uncorrected for referral bias) average 87%
and 89%, respectively; specificities (also uncorrected) average
73% and 75%.
2. Effect of Referral Bias
In estimating the true sensitivity and specificity of noninva-
sive testing, referral or work-up bias needs to be taken into
account. Table 7 in the full-text guideline summarizes studies
in which effects of referral bias have been estimated. Because
of the profound impact of referral bias on specificity, the
concept of the normalcy rate has been developed. The term
normalcy rate is used to describe the frequency of normal test
results in patients with a low likelihood of CAD, to differen-
tiate it from specificity.
TABLE 2. Recommendations for Use of Radionuclide Testing in Diagnosis, Risk Assessment, Prognosis, and
Assessment of Therapy After Acute STEMI
Patient Subgroup(s) Indication Test Class
Level of
Evidence
All 1. Rest LV function Rest RNA or ECG-gated SPECT I B
Thrombolytic therapy without
catheterization
2. Detection of inducible ischemia and
myocardium at risk
Stress MPI with ECG-gated SPECT
whenever possible
I B
Acute STEMI 3. Assessment of infarct size and
residual viable myocardium
MPI at rest or with stress using gated
SPECT
I B
4. Assessment of RV function with
suspected RV infarction
Equilibrium or FPRNA IIa B
ECG indicates electrocardiography; FPRNA, first-pass radionuclide angiography; LV, left ventricular; MPI, myocardial perfusion imaging; RNA,
radionuclide angiography; RV, right ventricular; SPECT, single-photon emission computed tomography; STEMI, ST-segment elevation myocardial
infarction.
TABLE 3. Recommendations for Use of Radionuclide Testing for Risk Assessment/Prognosis in Patients With NSTEMI
and UA
Indication Test Class
Level of
Evidence
1. Identification of inducible ischemia in the distribution of the “culprit
lesion” or in remote areas in patients at intermediate or low risk for
major adverse cardiac events.
Stress MPI with ECG gating
whenever possible
I B
2. Identification of the severity/extent of inducible ischemia in patients
whose angina is satisfactorily stabilized with medical therapy or in
whom diagnosis is uncertain.
Stress MPI with ECG gating
whenever possible
I A
3. Identification of hemodynamic significance of coronary stenosis after
coronary arteriography.
Stress MPI I B
4. Measurement of baseline LV function. RNA or gated SPECT I B
5. Identification of the severity/extent of disease in patients with ongoing
suspected ischemia symptoms when ECG changes are not diagnostic.
Rest MPI IIa B
ECG indicates electrocardiography; LV, left ventricular; MPI, myocardial perfusion imaging; RNA, radionuclide angiography; SPECT, single-photon
emission computed tomography.
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3. Quantitative Analysis
Quantitative analysis of myocardial perfusion SPECT has
been developed using a variety of approaches and, in general,
has similar sensitivities and specificities compared with those
of expert visual analysis.
4. ECG-Gated SPECT
The current state of the art is ECG-gated myocardial perfu-
sion SPECT (gated SPECT). The ability to observe myocar-
dial contraction in segments with apparent fixed perfusion
defects permits the nuclear test reader to discern attenuation
artifacts from true perfusion abnormalities. The ability of
gated SPECT to provide measurement of left ventricular (LV)
EF (LVEF), segmental wall motion, and absolute LV vol-
umes also adds to the prognostic information that can be
derived from a SPECT study.
5. Attenuation Correction
The field of attenuation correction continues to evolve rap-
idly, with some available systems having undergone more
detailed and successful clinical validation than others. On the
basis of current information and the rate of technology
improvement, the Society of Nuclear Medicine and the
American Society of Nuclear Cardiology have concluded that
attenuation correction has become a method for which the
weight of evidence/opinion is in favor of its usefulness (16).
6. Positron Emission Tomography
Studies involving several hundred patients (see Table 10 in
the full-text guideline) indicate that perfusion imaging with
positron emission tomography (PET) using dipyridamole and
either 82Rb or 13N ammonia is also a sensitive and specific
clinical means to diagnose CAD.
B. Management of Patients With Known or
Suspected Chronic CAD: Assessment of Disease
Severity, Risk Stratification, Prognosis
Nuclear tests are best applied for risk stratification in patients
with a clinically intermediate risk of a subsequent cardiac
event, analogous to the optimal diagnostic application of
nuclear testing to patients with an intermediate likelihood of
having CAD. Many of the major determinants of prognosis in
CAD can be assessed by measurements of stress-induced
perfusion and function. Studies including large patient sam-
ples have now demonstrated that factors estimating the extent
of LV dysfunction (LVEF, the extent of infarcted myocardi-
um, transient ischemic dilation of the LV, and increased lung
uptake) are excellent predictors of cardiac mortality. In
contrast, markers of provocative ischemia (exertional symp-
toms, electrocardiographic changes, the extent of reversible
perfusion defects, and stress-induced ventricular dyssynergy)
are better predictors of the subsequent development of acute
ischemic syndromes (17).
1. Nongated Myocardial Perfusion Imaging
Not withstanding the now well-demonstrated advantages of
gated imaging, nongated perfusion scintigraphy has played a
major role in risk stratification of CAD patients. The full-text
guideline summarizes studies of stress myocardial perfusion
imaging in definite or suspected CAD (see Table 12 in the
full-text guideline). Normal stress perfusion SPECT results
are consistently predictive of a less than 1% annual risk of
cardiac death or myocardial infarction.
2. Gated SPECT
The information contained in the combined assessment of
perfusion and function with gated myocardial perfusion
SPECT is likely to enhance its prognostic and diagnostic
content. The most common current approach combines post-
stress and/or rest LV function by gated SPECT with rest/
stress perfusion measurements.
3. Radionuclide Angiography
Rest LVEF is universally recognized as one of the most
important determinants of long-term prognosis in patients
with chronic stable CAD. Radionuclide angiography (RNA)
can also be helpful in evaluating dyspnea by establishing the
state of right ventricular (RV) and LV performance. LV
function during exercise reflects disease severity and pro-
vides prognostic information.
4. Cost Effectiveness
As indicated in the ACC/AHA 2002 Guideline Update for the
Management of Patients With Chronic Stable Angina (15),
cardiac imaging can serve as a gatekeeper to cardiac cathe-
terization to minimize the rate of normal catheterizations and
to enrich the angiographic population with a greater propor-
tion of patients with significant, yet treatable, disease.
5. Frequency of Testing
Considerations for follow-up testing are also summarized in
the ACC/AHA 2002 Guideline Update for the Management
of Patients With Chronic Stable Angina (15). If patients
develop new signs or symptoms suggesting a worsened
clinical state, repeat testing at the time of worsening would be
appropriate. In the absence of a change in clinical state, the
estimated patient risk after initial testing (high, intermediate,
or low, as defined earlier) should play an important role in
individual recommendations (18).
6. Evaluation of the Effects of Medical Therapy
Although the available evidence suggests that the efficacy of
therapy can be assessed with repeat SPECT procedures while
the patient is under the effects of the medical treatment,
information about the effects of medical therapy on outcomes
is limited.
C. Specific Patient Populations
1. African Americans
The role of noninvasive imaging has been studied infre-
quently in African Americans or other minorities. Normal rest
and stress SPECT perfusion studies have been associated
with higher rates of AMI and/or cardiac death in African
Americans than in other populations (19,20), but included
higher than usual cardiac risk patients and did not account for
the incidence of LV hypertrophy (LVH) (21).
2. Women
As discussed in the ACC/AHA 2002 Guideline Update for
Exercise Testing (22) (http://www.acc.org/clinical/guide-
lines/exercise/exercise_clean.pdf), the use of radionuclide
testing in women is influenced importantly by the later
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presentation of CAD in women than in men and by sex-
related limitations in exercise stress testing. These issues have
provoked interest in the potential additive benefit of stress
perfusion imaging in women, particularly those with at least
an intermediate likelihood of coronary disease (23–26).
3. Normal Resting ECG, Able to Exercise
Patients with a normal resting ECG constitute a large and
important subgroup. Most patients who present with multiple
risk factors with or without cardiac symptoms have a normal
resting ECG. Such patients are likely to have normal LV
function and an excellent prognosis. For these reasons, a
stepwise strategy is generally recommended in which an
exercise ECG, and not a stress imaging procedure, is per-
formed as the initial test in patients with an intermediate
pretest likelihood of CAD who are not taking digoxin, have a
normal resting ECG, and are able to exercise. A stress
imaging technique should be used for patients with wide-
spread rest ST depression (more than 1 mm), complete left
bundle-branch block (LBBB), ventricular-paced rhythm, pre-
excitation, or LVH with repolarization changes (15).
4. Intermediate-Risk Duke Treadmill Score
The Duke treadmill score combines various forms of infor-
mation from stress testing and provides a simple way to
calculate risk (27). Annual mortality rates according to risk
groups are presented in the ACC/AHA 2002 Chronic Stable
Angina Guideline Update (15). The score has been reported
to work well for both inpatients and outpatients and equally
well for men and women. Only a small number of elderly
patients, however, have been studied. Several studies have
demonstrated value of myocardial perfusion scintigraphy in
further risk assessment of patients with an intermediate score
associated with an intermediate risk of cardiac death (28–30).
5. Normal Resting ECG, Unable to Exercise
In patients with an intermediate to high likelihood of CAD
who have a normal resting ECG but are unable to exercise,
pharmacologic myocardial perfusion SPECT with adenosine
or dipyridamole has been shown to be highly effective in
diagnosis and risk stratification.
6. LBBB/Pacemakers
Pharmacologic stress perfusion imaging is preferable to
exercise perfusion imaging for purposes of both diagnosis
and risk stratification (31,32). Several studies have observed
an increased prevalence of myocardial perfusion defects
during exercise imaging, in the absence of angiographic
coronary disease, in patients with LBBB. Given that ECG
testing is nondiagnostic in patients with ventricular pacing in
a manner similar to that observed with LBBB, it is likely that
the considerations with regard to the use of radionuclide
techniques for diagnostic and risk stratification purposes in
patients with ventricular pacemakers are the same as those
applied to patients with LBBB.
7. Left Ventricular Hypertrophy
In patients with LVH, with or without resting ST-segment
abnormality, ST depression during exercise is frequently
present in the absence of significant CAD. In these patients,
stress nuclear techniques have similar diagnostic sensitivity
and specificity to those observed in patients without LVH.
The diagnostic value of myocardial perfusion SPECT is not
generally degraded by the presence of hypertension without
evidence of LVH (33), although an increased frequency of
false-positive studies has been reported in athletes (34).
Similarly, although the number of reports is small, the
prognostic value of myocardial perfusion SPECT in patients
with LVH appears to be equal to that observed in patients
without LVH (35).
8. Patients With Nonspecific ST-T-Wave Changes
Patients with nonspecific ST-T-wave changes, such as might
occur with digoxin, Wolff-Parkinson-White syndrome
(WPW), or other conditions, are considered to have nondi-
agnostic stress ECG responses with regard to ST-segment
depression. Although there are limited data on the diagnostic
and prognostic information for myocardial perfusion SPECT
in these patients, those with intermediate to high likelihood of
coronary disease can perhaps be effectively assessed for
detection and risk stratification with myocardial perfusion
SPECT.
9. Elderly
Prognostic value of perfusion scintigraphy in elderly patients
has been reported (36).
10. Asymptomatic Patients
The relatively low prevalence of CAD and risk of future
events will affect the performance of any diagnostic test in a
manner predictable by Bayesian principles (ie, positive pre-
dictive value will usually be low). It is not clear that detecting
asymptomatic preclinical CAD will lead to therapeutic inter-
vention that will reduce risk beyond that indicated by risk
factor profiling and currently recommended strategies to
reduce risk (37).
Persons whose occupations may affect public safety (eg,
airline pilots, truckers, bus drivers) or who are professional or
high-profile athletes commonly undergo periodic exercise
testing for statutory reasons (22). In some asymptomatic
patients, testing may be appropriate when there is a high-risk
clinical situation (eg, diabetes or multiple risk factors) (22).
Patients with a more than 20% 10-year risk of developing
coronary heart disease are considered to be at high risk in
current National Cholesterol Education Program guidelines
(37).
11. Obese Patients
Very obese patients constitute a special problem because
most imaging tables used for SPECT have weight-bearing
limits (often 300 lb [135 kg]) that preclude imaging very
heavy subjects. These subjects can still be imaged by planar
scintigraphy.
12. Diabetes
The increasing recognition of diabetes mellitus as a major
risk factor for cardiovascular disease (38) has heightened
interest in myocardial perfusion imaging for CAD diagnosis
and risk stratification. Available studies are based on retro-
spective analyses of patients referred to the nuclear cardiol-
ogy laboratory (24,39,40). Prospective information in asymp-
tomatic diabetic patients drawn from the general diabetic
1323JACC Vol. 42, No. 7, 2003 Klocke et al.
October 1, 2003:1318–33 ACC/AHA Guidelines for Cardiac Radionuclide Imaging
population is awaited (41). Currently available studies indi-
cate that (1) 99mTc-sestamibi myocardial perfusion SPECT has
comparable sensitivity, specificity, and normalcy rates for the
diagnosis of CAD in diabetic and nondiabetic patients; (2)
risk-adjusted event-free survival in patients with mildly and
moderately to severely abnormal scans is worse in patients
with diabetes than in those without diabetes; (3) the presence
and extent of myocardial perfusion SPECT abnormality is an
independent predictor of cardiac death alone, or of cardiac
death and MI, in patients with or without diabetes; and (4)
diabetic women have the worst outcome for any given extent
of reversible myocardial defect.
13. After Coronary Calcium Screening
Although some patients can benefit from nuclear stress
testing after electron-beam CT, it would clearly not be
cost-effective for all patients with atherosclerosis according
to electron-beam CT to go on to the more expensive nuclear
cardiology testing. In general, when the electron-beam CT
score is higher than the 75th percentile for age and sex, stress
nuclear testing may sometimes be appropriate for purposes of
risk stratification.
14. Before and After Revascularization
a. Radionuclide Imaging Before Revascularization Interven-
tions
When there is uncertainty with regard to the appropriate
choice of therapy after coronary angiography, stress nuclear
testing can risk stratify 25% to 75% lesions usefully (42).
b. Radionuclide Imaging After Percutaneous Coronary Inter-
vention
The ACC/AHA 2002 Guideline Update for Exercise Test-
ing (22) summarizes the available information on exercise
testing after percutaneous coronary intervention (PCI). Symp-
tom status is an unreliable index of development of resteno-
sis, with 25% of asymptomatic patients documented as
having ischemia on exercise testing. Myocardial perfusion
imaging can be helpful in appropriately selected patients. The
major indication for perfusion imaging in patients after
successful PCI is to evaluate symptoms suggesting new
disease.
c. Radionuclide Imaging After Coronary Artery Bypass Graft
Surgery
Myocardial perfusion scintigraphy can be useful in deter-
mining the location, extent, and severity of ischemia. Prog-
nostic value has been demonstrated both early (43) and late
(44,45) after coronary artery bypass graft (CABG) surgery.
15. Radionuclide Imaging Before Noncardiac Surgery
The ACC/AHA Guideline Update for Perioperative Cardiac
Evaluation for Noncardiac Surgery (46) (http://www.acc.org/
clinical/guidelines/perio/update/pdf/perio_update.pdf) has
emphasized the importance of clinical, demographic, and
surgical indicators of risk. In general, noninvasive preopera-
tive testing is best directed at patients considered to be at
intermediate clinical risk (diabetes, stable CAD, compensated
heart failure) who are scheduled to undergo intermediate- or
high-risk surgery. A thorough evaluation of appropriately
selected patients will also afford an assessment of cardiac
prognosis over the long term. Exercise stress is preferred in
patients capable of achieving adequate workloads; radionu-
clide techniques should be reserved for patients whose
baseline ECGs render exercise interpretation invalid or who
require pharmacologic stress because of the inability to
exercise.
a. Myocardial Perfusion Imaging
The full-text guideline summarizes studies of perfusion
imaging in the preoperative assessment of cardiac risk for
vascular and nonvascular surgery (see Table 14 in the
full-text guideline). For patients with radionuclide evidence
of ischemia, the positive predictive value of such testing is
uniformly low, in the range of 4% to 20%. The negative
predictive value of a normal scan, however, is very high (96%
to 100%). Patients with reversible defects are at greater risk
for perioperative ischemia than are those with fixed defects;
the latter defects may, in turn, be a marker for longer-term
risk. The positive predictive value of perfusion imaging can
be improved when testing is applied selectively to patients
with a higher pretest likelihood of CAD and when the results
are integrated into a clinical risk assessment. If a noninvasive
assessment of ischemic jeopardy before noncardiac surgery is
necessary, the choice between radionuclide stress perfusion
imaging and dobutamine stress echocardiography should be
made on the basis of institutional expertise and patient-
specific attributes.
b. Radionuclide Ventriculography
Exercise radionuclide ventriculography is rarely performed
to assess ischemic jeopardy before noncardiac surgery. The
evaluation of resting LV function, however, is an important
component of the preoperative assessment of patients with
symptoms and/or signs of heart failure. LV systolic function
is now routinely assessed with gated SPECT techniques at the
time of myocardial perfusion imaging. Not unexpectedly, the
risk of perioperative complications is highest among patients
with a resting LVEF more than 0.35. Reduced LV systolic
function is a predictor of perioperative heart failure but bears
no consistent correlation with the risk of perioperative
ischemia.
D. Recommendations
I. Cardiac Stress Myocardial Perfusion SPECT in Pa-
tients Able to Exercise: Recommendations for Diag-
nosis of Patients With an Intermediate Likelihood of
CAD and/or Risk Stratification of Patients With an
Intermediate or High Likelihood of CAD Who Are
Able to Exercise (to at least 85% of Maximal Pre-
dicted Heart Rate)
Class I
1. Exercise myocardial perfusion SPECT
to identify the extent, severity, and loca-
tion of ischemia in patients who do not
have LBBB or an electronically-paced
ventricular rhythm but do have a base-
line ECG abnormality that interferes
with the interpretation of exercise-
induced ST-segment changes (ventricu-
lar pre-excitation, LVH, digoxin ther-
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apy, or more than 1-mm ST depression).
(Level of Evidence: B)
2. Adenosine or dipyridamole myocardial
perfusion SPECT in patients with LBBB
or electronically-paced ventricular
rhythm. (Level of Evidence: B)
3. Exercise myocardial perfusion SPECT
to assess the functional significance of
intermediate (25% to 75%) coronary
lesions. (Level of Evidence: B)
4. Exercise myocardial perfusion SPECT in
patients with intermediate Duke treadmill
score. (Level of Evidence: B)
5. Repeat exercise myocardial perfusion
imaging after initial perfusion imaging
in patients whose symptoms have
changed to redefine the risk for cardiac
event. (Level of Evidence: C)
Class IIa
1. Exercise myocardial perfusion SPECT at 3
to 5 years after revascularization (either PCI
or CABG) in selected high-risk asymptom-
atic patients. (Level of Evidence: B)
2. Exercise myocardial perfusion SPECT
as the initial test in patients who are
considered to be at high risk (patients
with diabetes or patients otherwise de-
fined as having a more than 20% 10-
year risk of a coronary heart disease
event). (Level of Evidence: B)
Class IIb
1. Repeat exercise myocardial perfusion
SPECT 1 to 3 years after initial perfu-
sion imaging in patients with known or a
high likelihood of CAD and stable symp-
toms and a predicted annual mortality
of more than 1% to redefine the risk of
a cardiac event. (Level of Evidence: C)
2. Repeat exercise myocardial perfusion
SPECT on cardiac active medications
after initial abnormal perfusion imaging
to assess the efficacy of medical therapy.
(Level of Evidence: C)
3. Exercise myocardial perfusion SPECT in
symptomatic or asymptomatic patients
who have severe coronary calcification
(CT coronary calcium score more than the
75th percentile for age and sex) in the
presence on the resting ECG of pre-
excitation [Wolff-Parkinson-White syn-
drome] or more than 1 mm ST-segment
depression. (Level of Evidence: B)
4. Exercise myocardial perfusion SPECT in
asymptomatic patients who have a high-
risk occupation. (Level of Evidence: B)
II. Cardiac Stress Myocardial Perfusion SPECT in Pa-
tients Unable to Exercise: Recommendations for Di-
agnosis of Patients With an Intermediate Likelihood
of CAD and/or Risk Stratification of Patients With an
Intermediate or High Likelihood of CAD Who Are
Unable to Exercise.
Class I
1. Adenosine or dipyridamole myocardial
perfusion SPECT to identify the extent,
severity, and location of ischemia. (Level
of Evidence: B)
2. Adenosine or dipyridamole myocardial
perfusion SPECT to assess the func-
tional significance of intermediate (25%
to 75%) coronary lesions. (Level of Evi-
dence: B)
3. Adenosine or dipyridamole myocardial
perfusion SPECT after initial perfusion
imaging in patients whose symptoms
have changed to redefine the risk for
cardiac event. (Level of Evidence: C)
Class IIa
1. Adenosine or dipyridamole myocardial
perfusion SPECT at 3 to 5 years after
revascularization (either PCI or CABG)
in selected high-risk asymptomatic pa-
tients. (Level of Evidence: B)
2. Adenosine or dipyridamole myocardial
perfusion SPECT as the initial test in
patients who are considered to be at high
risk (patients with diabetes or patients
otherwise defined as having a more than
20% 10-year risk of a coronary heart
disease event). (Level of Evidence: B)
3. Dobutamine myocardial perfusion
SPECT in patients who have a contrain-
dication to adenosine or dipyridamole.
(Level of Evidence: C)
Class IIb
1. Repeat adenosine or dipyridamole myo-
cardial perfusion imaging 1 to 3 years
after initial perfusion imaging in pa-
tients with known or a high likelihood of
CAD and stable symptoms, and a pre-
dicted annual mortality of more than
1%, to redefine the risk of a cardiac
event. (Level of Evidence: C)
2. Repeat adenosine or dipyridamole myo-
cardial perfusion SPECT on cardiac ac-
tive medications after initial abnormal
perfusion imaging to assess the efficacy
of medical therapy. (Level of Evidence: C)
3. Adenosine or dipyridamole myocardial
perfusion SPECT in symptomatic or
asymptomatic patients who have severe
coronary calcification (CT Coronary
Calcium Score more than the 75th per-
centile for age and sex) in the presence
on the resting ECG of LBBB or an
electronically-paced ventricular rhythm.
(Level of Evidence: B)
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4. Adenosine or dipyridamole myocardial
perfusion SPECT in asymptomatic pa-
tients who have a high-risk occupation.
(Level of Evidence: C)
III. Cardiac Stress Myocardial Perfusion PET: Recom-
mendations for Diagnosis of Patients With an Inter-
mediate Likelihood of CAD and/or Risk Stratification
of Patients With an Intermediate or High Likelihood
of CAD
Class I
1. Adenosine or dipyridamole myocardial
perfusion PET in patients in whom an
appropriately indicated myocardial per-
fusion SPECT study has been found to be
equivocal for diagnostic or risk stratifica-
tion purposes. (Level of Evidence: B)
Class IIa
1. Adenosine or dipyridamole myocardial
perfusion PET to identify the extent,
severity, and location of ischemia as the
initial diagnostic test in patients who are
unable to exercise. (Level of Evidence: B)
2. Adenosine or dipyridamole myocardial
perfusion PET to identify the extent, se-
verity, and location of ischemia as the
initial diagnostic test in patients who are
able to exercise but have LBBB or an
electronically-paced rhythm. (Level of Ev-
idence: B)
IV. Cardiac Stress Perfusion Imaging Before Noncardiac
Surgery: Recommendations
Class I
1. Initial diagnosis of CAD in patients with
intermediate pretest probability of disease
and abnormal baseline ECG1 or inability
to exercise. (Level of Evidence: B)
2. Prognostic assessment of patients under-
going initial evaluation for suspected or
proven CAD with abnormal baseline
ECG1 or inability to exercise. (Level of
Evidence: B)
3. Evaluation of patients following a
change in clinical status (eg, ACS) with
abnormal baseline ECG1 or inability to
exercise. (Level of Evidence: B)
4. Initial diagnosis of CAD in patients with
LBBB and intermediate pretest proba-
bility of disease, when used in conjunc-
tion with vasodilator stress. (Level of
Evidence: B)
5. Prognostic assessment of patients with
LBBB undergoing initial evaluation for
suspected or proven CAD, when used in
conjunction with vasodilator stress.
(Level of Evidence: B)
6. Assessment of patients with intermedi-
ate or minor clinical risk predictors2 and
poor functional capacity (less than 4
METS) who require high-risk noncar-
diac surgery3, when used in conjunction
with pharmacologic stress. (Level of Ev-
idence: C)
7. Assessment of patients with intermedi-
ate clinical risk predictors2, abnormal
baseline ECGs1, and moderate or excel-
lent functional capacity (more than 4
METS) who require high-risk noncar-
diac surgery. (Level of Evidence: C)
Class IIb
1. Routine assessment of active, asymptom-
atic patients who have remained stable
for up to 5 years after CABG surgery.
(Level of Evidence: C)
2. Routine evaluation of active asymptom-
atic patients who have remained stable
for up to 2 years after previous abnor-
mal coronary angiography or noninva-
sive assessment of myocardial perfusion.
(Level of Evidence: C)
3. Diagnosis of restenosis and regional is-
chemia in active asymptomatic patients
within weeks to months after PCI. (Level
of Evidence: C)
4. Initial diagnosis or prognostic assess-
ment of CAD in patients with right
bundle-branch block or less than 1-mm
ST depression on resting ECG. (Level of
Evidence: C)
Class III
1. Routine screening of asymptomatic men
or women with low pretest likelihood of
CAD. (Level of Evidence: C)
2. Evaluation of patients with severe co-
morbidities that limit life expectancy or
candidacy for myocardial revasculariza-
tion. (Level of Evidence: C)
3. Initial diagnosis or prognostic assess-
ment of CAD in patients who require
emergency noncardiac surgery. (Level of
Evidence: C)
IV. Heart Failure
A. Introduction
The clinical syndrome of heart failure in adults is commonly
associated with the etiologies of ischemic and nonischemic
1Baseline ECG abnormalities that interfere with interpretation of
exercise-induced ST-segment changes include LBBB, ventricular pre-
excitation, ventricular pacing, LVH with repolarization changes, more
than 1-mm ST depression, and digoxin therapy.
2As defined in the ACC/AHA Guideline Update for Perioperative Cardio-
vascular Evaluation for Noncardiac Surgery (46), intermediate clinical risk
predictors include mild angina, prior MI, compensated or prior heart failure,
diabetes, and renal insufficiency. Minor clinical risk predictors include
advanced age, abnormal ECG, rhythm other than sinus, low functional
capacity, history of cerebrovascular accident, and uncontrolled hypertension.
3High-risk surgery is defined by emergent operations (particularly in the
elderly), aortic and other major vascular surgery, peripheral vascular surgery,
and other prolonged operations in which major fluid shifts are anticipated (ie,
reported cardiac risk often more than 5%).
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dilated cardiomyopathy, hypertrophic cardiomyopathy, hy-
pertensive heart disease, and valvular heart disease. Common
principles of assessment that influence prognosis and therapy
include the assessment of (1) LV function and remodeling,
(2) the contribution of myocardial ischemia due to CAD, and
(3) myocardial viability.
B. Assessment of LV Function
1. Assessment of LV Systolic Dysfunction
The clinician’s choice of noninvasive imaging modality to
detect and quantify LV systolic dysfunction in the individual
patient with heart failure depends on several variables,
including cost, ease of access at point-of-care, need for
precise computed quantitative measurement, and local exper-
tise. RNA can be used to compute quantitative estimates of
LV, as well as RV, EF, and absolute volumes. A strength of
RNA is that the quantitative computation of EF and chamber
volumes does not depend on mathematical assumptions of
ventricular geometry. Thus, radionuclide quantitative compu-
tations of LV chamber volume and EF are obtainable in
100% of patients. The long biological half-life of 99mTc-
labeled blood pool agents in gated equilibrium studies also
permits serial acquisition of data at rest and during exercise.
2. Assessment of LV Diastolic Dysfunction
The objective determination of the presence and severity of
diastolic dysfunction is increasingly important in patients
with the clinical syndrome of heart failure. The rate of change
of counts in diastole can be analyzed to calculate indices of
diastolic filling, including the peak LV filling rate, time to
peak filling, and atrial contribution to filling. In contemporary
practice, Doppler blood flow velocity indices of transmitral
flow are more commonly used to assess LV diastolic filling
parameters. Large population-based criteria, adjusted for age
and sex, for normal versus abnormal diastolic function using
RNA have not yet been established.
C. Assessment of CAD
1. Importance of Detecting CAD in Heart Failure Patients
Determining whether LV dysfunction is caused predomi-
nantly by the consequences of CAD or by one of the many
other etiologies included in the term “nonischemic” cardio-
myopathy is a critical early step in the management of heart
failure patients. Decisions about the need for cardiac cathe-
terization and coronary angiography will be informed by the
initial clinical and noninvasive assessment of these patients.
A significant subgroup of patients with heart failure and
underlying CAD has a potentially reversible degree of LV
dysfunction with revascularization.
2. Myocardial Perfusion Imaging to Detect CAD in Heart
Failure Patients
The sensitivity and negative predictive value of myocardial
perfusion imaging in detecting CAD in patients with heart
failure and LV dysfunction have been excellent in published
studies. However, it is not clear how these studies, some of
which involved relatively small numbers of patients and older
techniques, may generalize to current patients and contempo-
rary imaging techniques. The specificity of perfusion imaging
to rule out coronary disease is modest, on the average 40% to
50%. The frequent false-positive studies are due to perfusion
abnormalities in a significant number of patients with “nonis-
chemic” cardiomyopathy, ie, those patients without epicardial
coronary disease. Table 4 lists recommendations for radionu-
clide imaging in patients with heart failure.
D. Assessment of Myocardial Viability
1. Goals of Assessing Myocardial Viability
In patients with chronic coronary disease and LV dysfunc-
tion, an important subpopulation exists in which revascular-
ization may significantly improve regional or global LV
function, as well as symptoms and potentially natural history.
The underlying pathophysiology involves reversible myocar-
dial dysfunction (hibernation or stunning). Meta-analysis of a
substantial body of literature indicates that those with evi-
dence of preserved myocardial viability who underwent
revascularization had a substantial reduction in the risk of
death during long-term follow-up (47). If nonviability was
predominant, the risk of death was intermediate and not
affected by revascularization. These conclusions, however,
are limited by lack of randomization and the fact that
observational cohorts analyses are subject to selection biases.
TABLE 4. Recommendations for the Use of Radionuclide Imaging in Patients With Heart Failure:
Fundamental Assessment
Indication Test Class
Level of
Evidence
1. Initial assessment of LV and RV function at rest* Rest RNA I A
2. Assessment of myocardial viability for consideration of
revascularization in patients with CAD and LV systolic dysfunction
who do not have angina
MPI (see Table 5), PET I B
3. Assessment of the copresence of CAD in patients without angina MPI IIa B
4. Routine serial assessment of LV and RV function at rest Rest RNA IIb B
5. Initial or serial assessment of ventricular function with exercise Exercise RNA IIb B
*National consensus treatment guidelines are directed by quantitative assessment of LVEF and identification of LVEF less than or
equal to 40%.
CAD indicates coronary artery disease; LV, left ventricular; MPI, myocardial perfusion imaging; PET, positron emission tomography;
RNA, radionuclide angiography.
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2. General Principles of Assessing Myocardial Viability by
Radionuclide Techniques
Preservation of myocardial viability exists as a spectrum in a
territory with regional ventricular dysfunction, from the
possibility of no preserved viability (ie, complete transmural
infarction) to completely preserved viability (ie, transmural
hibernation or stunning with the potential for full recovery of
function). Most studies evaluating the radionuclide tech-
niques for assessing viability have focused on analysis of
resting tracer uptake (as with 201Tl, sestamibi, or tetrofosmin)
or evidence of preserved metabolic activity at rest (by
18F-2-fluorodeoxyglucose [FDG] or 11C-acetate).
3. Techniques and Protocols for Assessing Myocardial
Viability
a. 201Tl Stress Redistribution
The uptake of 201Tl is an energy-dependent process requir-
ing intact cell membrane integrity, and the presence of 201Tl
implies preserved myocyte cellular viability. The redistribu-
tion properties of 201Tl have been used as an important marker
of myocardial viability in stress imaging followed by a 3- to
4-hour redistribution image. The presence of a reversible
perfusion defect and/or preserved 201Tl uptake on the 3- to
4-hour redistribution images is an important sign of regional
viability.
b. 201Tl Reinjection
The 2 most widely studied protocols for assessing viability
in the presence of an inconclusive result on initial stress/
redistribution imaging involve 201Tl reinjection and late redis-
tribution imaging. The presence of a severe 201Tl defect after
reinjection identifies areas with a very low probability of
improvement in function.
c. Late Redistribution Imaging
Although improvement in uptake on late redistribution
images (24 to 48 hours after the initial stress 201Tl injection)
has good positive predictive value for identifying regions
with potential improvement in function, the negative predic-
tive value is suboptimal in some patients.
d. 201Tl Rest Redistribution
The identification of a “reversible resting defect” (in 3- to
4-hour versus 15- to 20-minute images) generally reflects
preserved viability. The finding appears to be an insensitive
though specific sign of potential improvement in regional
function.
e. 99mTc-Sestamibi and Tetrofosmin
Although the 99mTc-based tracers sestamibi and tetrofosmin
do not share the redistribution properties of 201Tl, their
performance characteristics for predicting improvement in
regional function after revascularization appear to be similar
to those seen with 201Tl.
f. PET Imaging
Positron tracers of blood flow and metabolism have been
extensively studied for evaluation of myocardial viability.
The most commonly used PET protocol involves evaluation
of myocardial glucose metabolism with 18F-FDG in conjunc-
tion with PET or SPECT examination of MBF with 13N-
ammonia or 99mTc-sestamibi, respectively. This approach
appears to have slightly better overall accuracy for predicting
recovery of regional function after revascularization than do
single-photon techniques (48). The magnitude of improve-
ment in heart failure symptoms after revascularization in
patients with LV dysfunction correlates with the preoperative
extent of 18F-FDG “mismatch” pattern (49).
Table 5 lists recommendations for the use of radionuclide
techniques to assess myocardial viability.
4. Image Interpretation for Myocardial Viability:
Quantitative Versus Visual Analysis of Tracer Activities
Whether quantitative analysis of tracer uptake in radionuclide
techniques is required for assessing viability is not estab-
lished. Visual analyses need to be at least semiquantitative,
accounting for defect severity.
5. Comparison of Techniques
All radionuclide techniques (and dobutamine echocardiography)
perform in a relatively similar manner with regard to positive
and negative predictive values for predicting improvements in
regional function (48). A meta-analysis of outcome studies
TABLE 5. Recommendations for the Use of Radionuclide Techniques to Assess Myocardial Viability
Indication Test Class Level of Evidence
1. Predicting improvement in regional and
global LV function after revascularization
Stress/redistribution/reinjection 201Tl
Rest-redistribution imaging
Perfusion plus PET FDG imaging
Resting sestamibi imaging
Gated SPECT sestamibi imaging
Late 201Tl redistribution imaging
(after stress)
Dobutamine RNA
Postexercise RNA
Postnitroglycerin RNA
I
I
I
I
IIa
IIb
IIb
IIb
IIb
B
B
B
B
B
B
C
C
C
2. Predicting improvement in heart failure
symptoms after revascularization.
Perfusion plus PET FDG imaging IIa B
3. Predicting improvement in natural history
after revascularization
201Tl imaging (rest-redistribution and
stress/redistribution/reinjection)
Perfusion plus PET FDG imaging
I
I
B
B
FDG indicates flurodeoxyglucose; PET, positron emission tomography; RNA, radionuclide angiography; SPECT, single-photon
emission computed tomography; 201Tl, thallium-201.
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related to myocardial viability has demonstrated no difference
among techniques commonly used to assess viability (PET
versus single-photon radionuclide versus dobutamine echocar-
diography) with regard to reduction of mortality or unfavorable
cardiac events after revascularization (47).
E. Etiologies of Heart Failure
1. Dilated Cardiomyopathy
Table 6 lists recommendations for the use of radionuclide
imaging to diagnose specific causes of dilated
cardiomyopathy.
2. Dilated Cardiomyopathy Due to Doxorubicin/
Anthracycline Cardiotoxicity
RNA is an ideal noninvasive tool to provide longitudinal
quantitative assessment of LV function in patients receiving
doxorubicin and other anthracyclines such as epirubicin. EF
should be measured in all patients before receiving doxoru-
bicin; those with pre-existing heart disease and/or LV dys-
function are at greater risk of congestive heart failure.
Continued use of doxorubicin after LV dysfunction has
developed causes progressive chamber dilatation and deteri-
oration in systolic function. Therapy with trastuzumab, a
monoclonal antibody directed against the HER2 receptor,
may increase the risk of developing heart failure during
standard-dose doxorubicin therapy (50). Radionuclide evalu-
ation of EF is also important in monitoring the cardioprotec-
tive effects of agents such as dexrazoxane when doxorubicin
is used in high dosages for solid malignant tumors (51).
3. Dilated Cardiomyopathy Due to Myocarditis
Radioisotope imaging has been reported to identify myocar-
ditis of diverse etiologies with gallium (which detects inflam-
mation), antimyosin antibody (which detects myocardial
necrosis and is myosin specific), and metaiodobenzylguani-
dine (MIBG; which assesses adrenergic neuronal function).
The usefulness of radionuclide imaging to detect myocarditis
in heart failure patients is not well established, however, and
data describing use of this approach are based on nonrandom-
ized studies.
4. Posttransplantation Rejection and Allograft
Vasculopathy
111In antimyosin antibody imaging has been described as a
technique to detect rejection after cardiac transplantation in
small observational studies. Because of many false-positive
results, endomyocardial biopsy continues to be the technique
of choice for serial monitoring and detection of acute rejec-
tion. Radionuclide evaluation of allograft vasculopathy, the
TABLE 7. Recommendations for the Use of Radionuclide Imaging to Evaluate
Hypertrophic Heart Disease
Indication Test Class
Level of
Evidence
1. Diagnosis of CAD in hypertrophic
cardiomyopathy
Rest and exercise
perfusion imaging
IIb B
2. Diagnosis and serial monitoring of
hypertensive hypertrophic heart disease
Rest RNA IIb B
3. Diagnosis and serial monitoring of
hypertrophic cardiomyopathy, with and
without outflow obstruction
Rest RNA III B
CAD indicates coronary artery disease; RNA, radionuclide angiography.
TABLE 6. Recommendations for the Use of Radionuclide Imaging to Diagnose Specific Causes of
Dilated Cardiomyopathy
Indication Test Class
Level of
Evidence
1. Baseline and serial monitoring of LV function
during therapy with cardiotoxic drugs (eg,
doxorubicin)
Rest RNA I A
2. RV dysplasia Rest RNA IIa B
3. Assessment of posttransplant obstructive CAD Exercise perfusion imaging IIb B
4. Diagnosis and serial monitoring of Chagas
disease
Exercise perfusion imaging IIb B
5. Diagnosis of amyloid heart disease 99mTc-pyrophosphate imaging IIb B
6. Diagnosis and serial monitoring of sarcoid
heart disease
Rest perfusion imaging
Rest 67Ga imaging
IIb
IIb
B
B
7. Detection of myocarditis Rest 67Ga imaging
111In antimyosin antibody imaging
IIb
IIb
B
C
67Ga indicates gallium-67; 99mTc-pyrophosphate, Tc-99m-pyrophosphate; 111In, indium-111; CAD, coronary artery disease; LV, left
ventricular; RNA, radionuclide angiography; RV, right ventricular.
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major limitation for long-term survival in transplant recipi-
ents, is limited by variable sensitivity and specificity. A
SPECT study with no reversible perfusion defects may be
useful in excluding coronary lesions appropriate for revascu-
larization (52).
5. Chagas Myocarditis and/or Cardiomyopathy
Chagas myocarditis and/or cardiomyopathy has several dis-
tinctive features in comparison with dilated cardiomyopathy
due to presumed viral myocarditis. Observational studies
using RNA and perfusion imaging have reported that chronic
Chagas cardiomyopathy is frequently associated with LV
regional wall motion abnormalities and perfusion defects in
the absence of epicardial CAD, and RV dyssynergy is
common in asymptomatic patients with no other clinical signs
of heart failure (53). In correlative investigations, there has
been a topographic association between regional defects in
sympathetic denervation detected by 123I-MIBG imaging and
perfusion defects detected by 201Tl imaging (54).
6. Sarcoid Heart Disease
Myocardial SPECT with 99mTc-sestamibi has been used to
detect myocardial involvement in patients with sarcoidosis.
Perfusion defects are more common in the RV than the in LV
and correlate with atrioventricular block, heart failure, and
ventricular tachycardia of RV origin (55). These defects are
frequently reversible, which makes it unlikely that they
represent deposition of granulomata or fibrosis. 67Ga was
formerly used in sarcoidosis as a marker of the activity and
extent of the disease and for predicting the efficacy of
corticosteroids, but it has been largely superseded by serial
chest CT and pulmonary function tests.
7. Cardiac Amyloidosis
Radionuclide angiography enables assessment of diastolic
and systolic function, including peak filling rates and LV
filling volumes during rapid filling and atrial contraction,
respectively (56). 131I-MIBG imaging has indicated a high
incidence of sympathetically denervated but viable myocar-
dium (57). Although 99mTc-pyrophosphate imaging has been
reported to have diagnostic utility, echocardiography appears
to be more useful because it enables complete characteriza-
tion of the altered LV and RV myocardium, as well as
valvular and pericardial involvement.
8. RV Dysplasia
The RV in arrhythmogenic RV dysplasia is characterized by
marked dilatation and depressed EF, which can be readily
identified with RV RNA (58).
9. Hypertrophic Cardiomyopathy
Radionuclide angiographic studies are not usually indicated
in the diagnosis of hypertrophic cardiomyopathy. Chest pain
is a frequent symptom, raising the possibility of coexistent
CAD. However, fixed and reversible exercise-induced myo-
cardial perfusion defects suggesting scar or ischemia occur in
the absence of significant epicardial coronary artery stenoses.
Reversible perfusion defects may reflect ischemia related to
diminished coronary flow reserve or decreased sympathoneu-
ral function in hypertrophied areas. Table 7 lists recommen-
dations for the use of radionuclide imaging to evaluate
hypertrophic heart disease.
10. Hypertensive Heart Disease
RNA allows recognition of abnormal diastolic and systolic
function in hypertensive subjects, even when resting systolic
global function and regional function are normal. A signifi-
cant proportion of such patients have hypertensive hypertro-
phic heart disease.
Hypertension is common in patients presenting with chest
pain for stress testing in whom CAD is suspected. The role of
stress perfusion imaging in patients with and without LVH
has been covered in the section on Chronic Syndromes.
11. Valvular Heart Disease
a. Diagnosis and Risk Stratification
In daily practice, 2D Doppler echocardiography studies
have become the modality of choice for diagnosing valvular
heart disease. The potential usefulness of RNA in assessing
valvular heart disease stems from the ability of RNA to
quantify LV and RV function. In addition, myocardial per-
fusion imaging has been used to examine for the presence of
flow-limiting coronary disease, especially in aortic stenosis.
b. Aortic Stenosis
Because of the lack of specificity and sensitivity of angina
for the concomitant presence of coronary disease in aortic
TABLE 8. Recommendations for the Use of Radionuclide Imaging in Valvular Heart Disease
Indication Test Class
Level of
Evidence
1. Initial and serial assessment of LV and RV function Rest RNA I B
2. Initial and serial assessment of LV function Exercise RNA IIb B
3. Assessment of the copresence of coronary disease MPI IIb B
LV indicates left ventricular; RNA, radionuclide imaging angiography; RV, right ventricular; MPI, myocardial perfusion imaging.
TABLE 9. Recommendations for the Use of Radionuclide
Imaging in Adults With Congenital Heart Disease
Indication Test Class
Level of
Evidence
1. Initial and serial assessment of
LV and RV function
Rest RNA I B
2. Shunt detection and quantification FPRNA IIa B
FPRNA indicates first-pass radionuclide angiography; LV, left ventricular; RV,
right ventricular; RNA, radionuclide angiography.
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stenosis, there has been much interest in the use of myocar-
dial perfusion imaging in preoperative evaluation. The sen-
sitivity and specificity of stress perfusion are relatively good
but probably not adequate for patients about to undergo valve
surgery. Thus, in practice, perfusion imaging has not sup-
planted coronary angiography in the preoperative work-up of
patients with aortic stenosis.
c. Aortic Regurgitation
The most promising use of RNA in valvular heart disease
initially appeared to be in the evaluation of patients with
aortic regurgitation, in whom a failure of EF to rise during
exercise seemed to mark the onset of LV dysfunction and
predict a poorer prognosis or indicate that the asymptom-
atic patient would soon become symptomatic (59). Subse-
quent studies indicated that exercise angiography does not
usually add additional prognostic information to the mea-
surement of resting LVEF and end-systolic dimension in
predicting the response to aortic valve replacement (60).
Enhanced prognostic ability of exercise RNA has been
reported when the calculation of systolic wall stress is
added (61).
d. Mitral Regurgitation
Perhaps the most compelling current use of RNA in
valvular heart disease is in the preoperative evaluation of
patients with mitral regurgitation. The echocardiogram
does not evaluate RV function well, whereas RV function
assessment is a strength of RNA. As with aortic regurgi-
tation, resting EF is a useful guide to valve repair or
replacement. Again, however, Doppler echocardiography
can make this assessment and add other anatomic and
prognostic information. RNA is useful postoperatively in
gauging changes in LV and RV performance. Table 8 lists
recommendations for the use of radionuclide imaging in
valvular heart disease.
12. Adults With Congenital Heart Disease
As in other forms of heart disease, RNA can be used
effectively to assess RV and LV systolic performance. In
addition, left-to-right shunting causes persistently high levels
of activity in the lung or RV during FPRNA because of early
recirculation. The resultant time-activity curve can be used to
calculate pulmonary to systemic flow ratios. The early
appearance of tracer in the left chambers of the heart can be
used to detect right-to-left shunts. 99mTc RNA appears to be
useful in evaluating abnormal lung flow after the Fontan and
Glenn procedures (62).
In general, however, radionuclide studies are now utilized
infrequently in assessing congenital heart disease and are
unlikely to be accurate if performed only occasionally. Table
9 lists recommendations for the use of radionuclide imaging
in adults with congenital heart disease.
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